

SMi Group Releases Agenda for the 3rd Annual Summit on Antibody Drug Conjugates

SMi group announces that registration is now live for the 3rd annual ADC Summit: Making your smart bomb smarter – creating innovative antibody-drug conjugates.

LONDON, LONDON, UNITED KINGDOM, January 17, 2014 /EINPresswire.com/ -- Antibody Drug Conjugates (ADCs) offer the promise and potential of delivering powerful tumour-killing activity with the advantage of reduced side effects for cancer patients. With the ADC market forecasted to reach \$9 billion by 2023, scientists believe that further improvements and research in ADC design can result in a new generation of agents.

Following on from this, SMi's 3rd annual [ADC Summit](#) comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies.

Key speakers this year include:

- Dr Mahendra Deonarain, Chief Scientific Officer, Photobiotics
- Dr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmune
- Philip Howard, PhD, Chief Scientific Officer, Spirogen Limited
- Dr Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
- Dr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, Synthron
- Dr Erica Hong, Scientist, ImmunoGen
- Dr Hagop Youssoufian, Executive Vice President of R&D, Progenics
- Dr Pamela Trail, Vice President Oncology, Regeneron



Good insight into industry knowledge and needs
University College London



To view the full speaker line-up visit the conference website at www.adcsummit.com

ADC Summit 2014 will aim to provide:

- Cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challenges
- Peer to peer networking opportunities with industry and academic opinion leaders including Photobiotics, MedImmune, Spirogen, Synthron plus many more...
- The latest developments pertaining to the components of ADCs (payload, antibody and linker)
- Round table sessions to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal

[Click here](#) to download the brochure which has just been released.

For those wishing to attend, there is currently a £300 early bird discount which expires on 28th February. Visit www.adcsummit.com

3rd Annual ADC Summit
19th-20th May 2014
Holiday Inn Regents Park Hotel
London UK
www.adcsummit.com

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.